Literature DB >> 15207701

Cloning and characterization of novel isoforms of the human kallikrein 6 gene.

Georgios Pampalakis1, Lisa Kurlender, Eleftherios P Diamandis, Georgia Sotiropoulou.   

Abstract

Human kallikrein 6 (protease M/zyme/neurosin) was originally identified based on its aberrant expression in tumor cells and is considered a biomarker for ovarian cancer. Here, we describe the identification, cloning, and tissue expression of three novel transcript variants of the KLK6 gene that encode for wild-type kallikrein 6. Contrary to the classical form, transcript variants contain one untranslated exon, exploit intronic sequences, and are likely products of alternative promoters. In addition, we cloned splice variants 2 and 3 produced by splicing out exons 3 and 4, respectively. Given the potential diagnostic applications of kallikrein 6 at both the mRNA and protein levels, we developed a duplex RT-PCR, in order to differentially detect and quantitate mRNA species corresponding to splice variants. We show that in normal mammary epithelial cells and mammary tumor cell lines that overexpress the KLK6 gene, splice variants account for approximately 10-20% of all mRNA species.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15207701     DOI: 10.1016/j.bbrc.2004.04.205

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

1.  Structural characterization and expression of five novel canine kallikrein-related peptidases in mammary cancer.

Authors:  Katerina Angelopoulou; George S Karagiannis
Journal:  Mamm Genome       Date:  2010-09-19       Impact factor: 2.957

Review 2.  Activity-Based Probes for Proteases Pave the Way to Theranostic Applications.

Authors:  Georgia Sotiropoulou; Eleni Zingkou; Evangelos Bisyris; Georgios Pampalakis
Journal:  Pharmaceutics       Date:  2022-04-30       Impact factor: 6.525

Review 3.  Functional roles of human kallikrein-related peptidases.

Authors:  Georgia Sotiropoulou; Georgios Pampalakis; Eleftherios P Diamandis
Journal:  J Biol Chem       Date:  2009-10-09       Impact factor: 5.157

4.  Effects of the demethylating agent, 5-azacytidine, on expression of the kallikrein-kinin genes in carcinoma cells of the lung and pleura.

Authors:  Joshua Wong; Yee Yen Sia; Neil L Misso; Shashi Aggarwal; Angeline Ng; Kanti D Bhoola
Journal:  Patholog Res Int       Date:  2011-09-04

5.  Lymph node tissue kallikrein-related peptidase 6 mRNA: a progression marker for colorectal cancer.

Authors:  L Ohlsson; G Lindmark; A Israelsson; R Palmqvist; Å Öberg; M-L Hammarström; S Hammarström
Journal:  Br J Cancer       Date:  2012-06-14       Impact factor: 7.640

6.  Transcriptional upregulation of human tissue kallikrein 6 in ovarian cancer: clinical and mechanistic aspects.

Authors:  S J C Shan; A Scorilas; D Katsaros; E P Diamandis
Journal:  Br J Cancer       Date:  2007-01-29       Impact factor: 7.640

7.  The use of kallikrein-related peptidases as adjuvant prognostic markers in colorectal cancer.

Authors:  M Talieri; L Li; Y Zheng; D K Alexopoulou; A Soosaipillai; A Scorilas; D Xynopoulos; E P Diamandis
Journal:  Br J Cancer       Date:  2009-04-14       Impact factor: 7.640

8.  Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathy.

Authors:  Malin Wennström; Yulia Surova; Sara Hall; Christer Nilsson; Lennart Minthon; Fredrik Boström; Oskar Hansson; Henrietta M Nielsen
Journal:  PLoS One       Date:  2013-01-08       Impact factor: 3.240

9.  Development and immunochemical evaluation of a novel chicken IgY antibody specific for KLK6.

Authors:  Georgia Sotiropoulou; Georgios Pampalakis; Evangelia Prosnikli; Gregory P Evangelatos; Evangelia Livaniou
Journal:  Chem Cent J       Date:  2012-12-05       Impact factor: 4.215

10.  Genome-wide analysis of alternative promoters of human genes using a custom promoter tiling array.

Authors:  Gregory A C Singer; Jiejun Wu; Pearlly Yan; Christoph Plass; Tim H M Huang; Ramana V Davuluri
Journal:  BMC Genomics       Date:  2008-07-25       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.